HOME > ACADEMIA
ACADEMIA
- University of the Ryukyus to Test Gout Drug Colchicine for COVID-19
November 6, 2020
- NCC Verifies Utility of Genomic Analysis by Liquid Biopsy
October 7, 2020
- Japanese Nephrology Society Publishes Recommendation on Use of HIF-PH Inhibitors
October 2, 2020
- Personalized Approach Needed for HFpEF Treatment with Entresto: Professor
August 28, 2020
- Fabricated Data Found in 5 Papers by Ex-NCVC/Osaka Univ. Doctor; 1 Used to Design JANP Study
August 21, 2020
- Generic APIs at Crossroads - 4: Professor Calls for Monitoring Drugs Liable to Be in Short Supply, Drawing Up Lists of Substitutes
August 17, 2020
- Generic APIs at Crossroads - 3: Gx Society Sets Up Committee for Discussions with Healthcare Providers and API Manufacturers
August 14, 2020
- Infectious Diseases Society Proposes Testing for Both COVID-19, Flu as It Girds for Simultaneous Outbreaks
August 7, 2020
- NCC, BrightPath Identify Peptide Vaccine Candidates for COVID-19
July 31, 2020
- Avigan Fails to Hit Statistical Significance in COVID-19 Trial: Fujita Health Univ.
July 13, 2020
- Univ. of Tokyo, Biogen Expand Neurological Research Program for 2 Years
July 9, 2020
- Kyoto University, NIBIOHN to Join Forces on Drug Discovery
July 8, 2020
- Nobel Laureate Honjo Sues Ono over Opdivo Royalties, Demands 22.6 Billion Yen
June 22, 2020
- NIID Aims to Start Preclinical Trials for Coronavirus Vaccines in Autumn: Flu Center Director
June 10, 2020
- Remdesivir Not Used as Severe Cases Decreased, Avigan/Alvesco Given to Several Dozen Patients: TMDU Hospital
June 5, 2020
- AnGes/Osaka Univ. Plan Small COVID-19 Vaccine Study from July, Larger One from September
June 5, 2020
- Kyoto Univ. to Launch Alzheimer’s Trial: iPSC-Based Drug Repositioning Project
June 5, 2020
- Japan to Join NIH’s Remdesivir-Baricitinib Combo Trial for COVID-19
June 1, 2020
- 26 Patients Enrolled in Alvesco’s Novel Coronavirus Trial: NCGM
June 1, 2020
- Nagasaki Univ. to Launch Clinical Trial for Nelfinavir for COVID-19
May 28, 2020
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
